Sixteenth of the " Immunotherapy for Resectable Non-Small Cell Lung Cancer" and the last webinar for 2020 ASCO Direct China series

About this Event

Webinar Date:

  • China Time: Saturday, November 14th, 8:00 AM
  • US EST Time: Friday, November 13th, 7:00 PM
  • US PST Time: Friday, November 13th, 4:00 PM

Conference Language: English

Venue: Live Zoom Webinar

Webinar Agenda

8:30am Opening Video

8:35am Chairperson Remarks

  • Professor He Jianxing, The First Affiliate Hospital of Guangzhou Medical University
  • Professor Gao Shugeng, Cancer Hospital Chinese Academy of Medical Sciences
  • K. Robert Shen, M.D., Mayo Clinic

8:45am BeiGene Innovative New Drug: BeiGene R&D pipeline introduction

  • Wang Lai, M.D., BeiGene

Session1 Hosts:K. Robert Shen, M.D. / Professor Haiquan Chen

8:55am Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA)

  • Dr. Roy S. Herbst, Yale School of Medicine

9:10am Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer: Insights from NADIM trial biomarkers

  • Dr. Alberto Cruz Bermudez, Puerta de Hierro Hospital

9:25am Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial (LCMC3 Trial)

  • Dr. Filiz Oezkan, Ohio State University

9:40am Panel Discussion

  • Dr. K. Robert Shen, Mayo Clinic
  • Dr. Haiquan Chen, Fudan University Shanghai Cancer Center
  • Dr. Roy S. Herbst, Yale School of Medicine
  • Dr. Alberto Cruz Bermudez, Puerta de Hierro Hospital
  • Dr. Filiz Oezkan, Ohio State University
  • Dr. Hongxu Liu, Liaoning Provincial Cancer Hospital
  • Dr. Lijie Tan, Fudan University Zhongshan Hospital
  • Dr. Wenhua Liang, The First Affiliated Hospital of Guangzhou Medical University
  • Dr. Shuben Li, The First Affiliated Hospital of Guangzhou Medical University

Session2 hosts: Professor Zhou Qinghua/ Professor Zhou Chengzhi

10:00am Lung cancer treatment with Tislelizumab: new progress and research plan

  • Professor Cui Jiz, The First Bethune Hospital of Jilin University

10:20am Structural optimization enabling infinite vitality - Interpretation of the pharmaceutical advantages of Tislelizumab

  • Li Kang, M.D., BeiGene

10:40am Masters' Insight

  • 1,What medicinal property shall be given priority in consideration for treating neo-adjuvant patients when selecting PD-1 inhibitors?
  • 2,What clinical benefit can be brought to surgery operation patients through structural optimization of Tislelizumab?
  • Professor Hu Jian, First Affiliated Hospital of Zhejiang University School of Medicine
  • Professor Ma Haitao, The First Affiliated Hospital of Soochow University
  • Professor Cheng Chao, The First Affiliated Hospital of Sun Yat-sen University
  • Professor Zhang Haibo, Guangdong Provincial Hospital of Traditional Chinese Medicine

Session3 Hosts: Professor Zhu Yuming/ Professor Jiang Tao

11:00am Outlook and thought on perioperative immunotherapy for lung cancer

  • Professor Tan Fengwei, Cancer Hospital Chinese Academy of Medical Sciences

11:20am Surgery operation and neo-adjuvant therapy: friend or foe?

  • Professor Zhang peng, Shanghai Pulmonary Hospital

11:40am Masters' Insight

1,How to regard the impact of immunotherapy to operations? and surgery operation?

2,What is the best treatment duration of immuno neo-adjuvant therapy and adjuvant therapy?

  • Professor Gu Chundong, The First Affiliated Hospital of Dalian Medical University
  • Professor Wang Dong, Taikang Xianlin Drum Tower Hospital, Nanjing University School of Medicine
  • Professor Pan Xiaojie, Fujian Provincial Hospital
  • Professor Lei Guangyan, Shaanxi Cancer Hospital

12:00am Chairperson Summary

  • Professor He Jianxing, The First Affiliate Hospital of Guangzhou Medical University
  • Professor Gao Shugeng, Cancer Hospital Chinese Academy of Medical Sciences

Speakers and Panelists Bio

Professor He Jianxing, The First Affiliate Hospital of Guangzhou Medical University

  • Guangdong Association of Thoracic Disease, President
  • Guangzhou Institute of Respiratory Health, President
  • National Clinical Research Center for Respiratory Disease, Deputy Director,
  • The First Affiliate Hospital of Guangzhou Medical University, Director of Thoracic Surgery Department and Oncology Department
  • Specialist who enjoys the State Council Special Allowance
  • Member of China Central Committee of Healthcare, Young Expert with outstanding contribution by Ministry of Health,
  • American College of Surgeons(ACS)Fellow
  • European Society Of Thoracic Surgeons(ESTS) Fellow
  • Royal College of Surgeons (FRCS)Fellow
  • American Association for Thoracic Surgery (AATS) Member
  • Society of Thoracic Surgeons(STS)Member
  • Engaged in the clinical and research of thoracic surgery for 34 years, leading the team to complete more than 3700 cases of various complex thoracic surgery including lung, heart-lung transplantation and minimally invasive tracheal and vascular reconstruction, and has achieved significant improvements in clinical efficacy. The innovative results are widely promoted and applied at home and abroad.
  • Published 246 SCI papers as the first author/corresponding author in Lancet, Nature Medicine, J Clin Oncol, Nat Commun, Ann Oncol, Ann Surg, etc., total IF: 1225.092 (IF>20 total 6 papers, IF>10 total 9 papers ), cited 3538 times by international journals such as Lancet, JAMA, 29 co-authors, IF: 283.688 (7 in IF>20), 228 Chinese papers in Chinese surgery, etc.; editor-in-chief of 8 monographs in English and 4 in Chinese; inventions 10 patents, 50 utility model patents, etc., with the first completion person won 1 National Science and Technology Progress Award (2018), China Medical Science and Technology Award and other provincial and ministerial science and technology awards 3 first prizes (2015, 2016, 2017) ), 2 second prizes of Chinese universities (1997, 2001); founded 2 SCI magazines "Journal of Thoracic Disease" and "Annals of Translational Medicine".

Professor Gao Shugeng, Cancer Hospital Chinese Academy of Medical Sciences

  • National cancer quality control center,Deputy Director
  • Cancer Hospital Chinese Academy of Medical Sciences, Vice President
  • Cancer Hospital Chinese Academy of Medical Sciences, Director of Thoracic Surgery
  • Royal College of Surgeons Fellowship
  • Chinese Society for Thoracic and Cardiovascular Surgery, Vice-chairman and Secretary General
  • Chinese Association of Thoracic Surgeons, Deputy President and Director General
  • Beijing Society for Thoracic Surgery, Chairman designate 
  • World Association of Chinese Oncologist, Vice Chairman
  • Chinese Journal of Minimally Invasive Surgery, Associate Editor-in-Chief
  • JTD Journal, Associate Editor-in-Chief
  • ATS Journal Chinese Version, Secretary General of Editorial Board

K. Robert Shen, M.D., Department of Surgery, Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota, USA

  • Dr. Shen is a Professor of Surgery and Consultant in the Division of General Thoracic Surgery at Mayo Clinic in Rochester, Minnesota, USA.
  • Dr. Shen received his undergraduate degree (A.B.) cum laude from Dartmouth College in Hanover, New Hampshire in 1987 and then received his M.D. degree with High Honors from Yale University School of Medicine, New Haven, Connecticut in 1995. He completed a residency in General Surgery at the Brigham & Women’s Hospital, Harvard Medical School, Boston, Massachusetts in 2002, which included a two year research fellowship at Harvard Medical School in gastrointestinal physiology. He then completed a residency in Thoracic Surgery at the Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts in 2004. Dr. Shen is certified by the American Board of Surgery as well as the American Board of Thoracic Surgery.
  • After completing his General Surgery and Thoracic Surgery training Dr. Shen joined the Thoracic Surgery faculty at the University of Virginia in Charlottesville, Virginia in 2005. He joined the Division of General Thoracic Surgery at the Mayo Clinic in 2007.
  • Dr. Shen is the Program Director of the Mayo Clinic Thoracic Surgery Residency Program. Dr. Shen has served in numerous national leadership positions in Thoracic Surgery. He has served on numerous committees and working groups for the Society of Thoracic Surgeons (STS), and was the Chair of the STS Workforce on Annual Meeting in 2016. Dr. Shen is also a member of the American Associate for Thoracic Surgery, and has been a Section Editor for SESATS XI and XII and XIII. Dr. Shen has been on the Program Committee for ASCO Gastrointestinal Cancers Symposium since 2016. He also is a reviewer for the Annals of Thoracic Surgery, The Journal of Thoracic & Cardiovascular Surgery and Diseases of the Esophagus.
  • Dr. Shen’s clinical practice and expertise spans the breadth of thoracic surgery and includes a specific interest in the treatment of benign and malignant esophageal disease.
  • He is author of more than 125 papers in peer-reviewed scientific journals such as The Annals of Thoracic Surgery, The Journal of Thoracic & Cardiovascular Surgery, The European Journal of Thoracic and Cardiovascular Surgery, Thoracic Surgery Clinics, Chest, and Diseases of the Esophagus, as well as the author of 13 textbook chapters.

Lai Wang, Ph.D., SVP, Head of Global Research and APAC Clinical Development

  • Over 10 years' experience in biotech industry and over 20 years in cancer research
  • Former Director of Research at Joyant Pharmaceuticals
  • Post-doc with Xiaodong Wang at Howard Hughes Medical Institute
  • Ph.D. from University of Texas Health Science Center at San Antonio
  • B.S. from Fudan University

Prof. Chen Haiquan, Fudan University Shanghai Cancer Center

  • President of Fudan University Thoracic Cancer Research Institute, Director of Fudan University Shanghai Cancer Center Thoracic Surgery Department, Team leader of Thoracic Cancer MDT, Director of Lung Cancer Center. Former President of Shanghai Thoracic Hospital.
  • Member of American Association for Thoracic Surgery(AATS), Committee Member of Education Committee(2019-), Committee Member of Thoracic surgery clinical practice standard committee(2020-), Society of Thoracic Surgeons(STS)Member, European Society Of Thoracic Surgeons(ESTS) Member. Chinese Association of Thoracic Surgeons, Deputy President. Member of the standing committee of China Anti Cancer Association Lung Cancer Committee, Member of Esophagus Cancer Committee. Associate Director of Chinese Society for Thoracic and Cardiovascular Surgery Esophagus Diseases, Deputy Chairman of CPAM lung cancer prevention and control, Vice Chairman of Shanghai Medical Association of Thoracic Surgery, Chairman of Shanghai anti cancer association lung cancer committee.
  • J THORAC CARDIOV SUR editorial board member, J CANCER RES CLIN Associate Editor-in-Chief ,Am J Transl Res、J Thorac Dis editorial board member .

Roy S. Herbst, MD, PhD?Yale Comprehensive Cancer Center | Yale School of Medicine | Smilow Cancer Hospital

  • Roy S. Herbst, MD, PhD is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT.
  • Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as Gefitinib, Cetuximab, Bevacizumab, Axitinib, Atezolizumab, and Pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His work on "umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he is at the forefront of personalized medicine and works closely with public-private partnerships to develop large clinical studies, such as Lung-MAP. He testified on this before the House of Representatives 21st Century Cures committee and served as a prominent figure in this area as a member of the NAM Policy forum for 9 years. The NCI Lung SPORE he leads has identified new mechanisms of sensitivity and resistance to immunotherapy. Dr. Herbst is a highly respected clinician­ scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer. He has also been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings,
  • Dr. Herbst has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.
  • Dr. Herbst was a member of the National Cancer Policy Forum, for which he organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research, where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair for developmental therapeutics for Southwestern Oncology Group’s (SWOG) Lung Committee. In 2015, his team at Yale was awarded a Lung Cancer SPORE by the NCI, and he serves as a principal investigator for a AACR/ Stand Up to Cancer Dream Team grant.
  • For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Dr. Alberto Cruz Bermudez,Puerta de Hierro Hospital

  • Dr. Alberto Cruz Bermudez currently coordinates the translational studies of the NADIM clinical trial of the Spanish Lung Cancer Group. Since 2015 he has been working at the research foundation of "Puerta de Hierro" Hospital, conducting research studies on lung cancer focusing on the tumour microenvironment and the search for biomarkers of response to therapies.
  • He has 10 years of experience in research in Oncology and Molecular Biology. He completed a pre-doctoral stay at the Karolinska Institute (Department of Metabolic Diseases). Bachelor’s in biology (Complutense University of Madrid), PhD in Molecular Biosciences focused on the relationship between mitochondrial DNA and cancer (Autonomous University of Madrid).

Filiz Oezkan, MD , Division of Medical Oncology, The Ohio State University, Columbus, Ohio?Department of Interventional Pulmonology, University Medicine Essen – Ruhrlandklinik, University Duisburg-Essen, Germany

  • Dr. Oezkan is a board-certified pulmonologist from Germany and currently performs postdoctoral research at the Ohio State University. Dr. Oezkan received her medical degree from Ruhr- University Bochum, Germany in 2008. She received her doctorate degree (Dr. med.) in Hepatitis C immunology Magna cum laude from Ruhr-University Bochum in 2012. She completed her residency and fellowship in Internal Medicine and Pulmonology in 2016. Since 2017 she performs postdoctoral research at the Ohio State University under the mentorship of Dr. David P. Carbone. She received a 2-year funding from the German Research Foundation (DFG) for her postdoctoral project “Investigation of Immune Modulation and its Correlation to Response in Early Stage Lung Cancer Patients Receiving Neo-Adjuvant Immunotherapy”. She was awarded for her work with a Merit Award by the Conquer Cancer Foundation of ASCO in 2019.
  • Her research focusses on translational immunophenotyping studies in lung cancer including bronchoscopically obtained tissues from lymph nodes and primary tumors.?To date, she has authored 19 peer-reviewed publications in highly cited journals such as American Journal of Respiratory and Critical Care Medicine, Clinical Lung Cancer and others. Dr. Oezkan has given several talks on international and national conferences, including the European Conference of Bronchology and Interventional Pulmonology, the World Conference on Lung Cancer (WCLC), the joint meeting of the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC) and has recently been invited to speak at the World Conference of Bronchology and Interventional Pulmonology (WCBIP) 2020.
  • In January 2021 Dr. Oezkan will be joining the Faculty of Medicine of Heidelberg University, Germany at the University Hospital Mannheim.

Professor Liu Hongxu

  • MD, Professor, Chief Physician, Doctoral Supervisor
  • Liaoning Provincial Cancer Hospital, Vice President, Director of Thoracic Surgery Department
  • Chairman of Liaoning Provincial Anti Cancer Association, Lung Cancer Committee
  • Chairman designate of Liaoning Association of Thoracic Surgery
  • Member of TNM Staging, International Association for the Study of Lung Cancer
  • Vice Chairman of liquid biopsy committee, China Lung Cancer Prevention and Treatment Alliance
  • Council of China Anti Cancer Association
  • Member of Lung Cancer Expert Committee, China Anti Cancer Association
  • Member of Mediastinal Tumor Expert Committee, China Anti Cancer Association
  • Member of Chinese Association of Thoracic Surgeons
  • Member of National Lung Cancer MDT Expert Committee
  • Member of Smart Healthcare Expert Committee of China Clinical Cancer Association
  • Honorary Chairman of Liaoning Alliance, China Lung Cancer Prevention and Treatment Alliance
  • Director of Liaoning Provincial Esophageal Cancer Key Lab
  • Liaoning Young and Famous Doctor
  • Key Talent of Liaoning Province Hundred-Thousand-Ten Thousand Talents Project

Professor Tan Lijie, Fudan University Zhongshan Hospital

  • Chief physician, doctoral supervisor, director of thoracic surgery, director of esophageal surgery, director of esophageal cancer center, Fudan University Zhongshan Hospital
  • Fellow of the American College of Surgeons (FACS)
  • AATS Member
  • Member of the Esophageal Disease Group of the Thoracic and Cardiovascular Surgery Branch of the Chinese Medical Association
  • Member of the Standing Committee of the Chinese Anti-Cancer Association Esophageal Cancer Professional Committee
  • Member of the Esophageal Surgery Expert Committee of the Chinese Physicians and Surgeons Branch
  • Director of Endoscopy Doctors Branch of Chinese Medical Doctor Association
  • Deputy Chairman of the Thoracic Surgery Professional Committee of the Cross-Strait Medical and Health Exchange Association
  • Standing Committee Member of Thoracic Surgery Branch of Chinese Research Hospital Association
  • Standing Committee Member of Thoracic Surgery Branch of China Association for International Exchange and Promotion of Healthcare
  • Standing Committee Member of Chinese Society of Esophageal Diseases (CSDE)

Professor Liang Wenhua, The First Affiliated Hospital of Guangzhou Medical University (National Respiratory Medicine Center),Department of Thoracic Oncology

  • Associate Chief Physician, Associate Professor, Doctoral Supervisor/Post-Doctoral Cooperative Tutor, Young Pearl River Scholar, Outstanding Young Medical Talent of Guangdong Province
  • Assistant to the President of Guangzhou Institute of Respiratory Health (Professor He Jianxing)
  • Secretary-General of Guangdong Society of Thoracic Diseases and Chairman of Immunotherapy Committee
  • Deputy Leader of the Lung Cancer Group of the State Key Laboratory of Respiratory Diseases, and backbone of the National Clinical Research Center
  • Young member of the Chinese Society of Clinical Oncology (CSCO), member of the NSCLC Committee and the Artificial Intelligence Committee
  • Associate Editor of Transl Lung Cancer Res (IF 4.8), Editorial Board Member of J Thorac Dis and Ann Transl Med
  • He graduated from the eight-year clinical medicine program of Sun Yat-sen University (supervisor: Professor Zhang Li), and was an outstanding graduate of 2014. Mainly engaged in comprehensive diagnosis and treatment of lung cancer and clinical translational research. So far, more than 120 SCI papers have been published, 13 with a score of 10 or more, and 20 with a score of 5 or more. The cumulative impact factor is 650+, the total number of citations is 1600+, and the H index is 21, including 86 first/corresponding authors, including :J Clin Oncol (IF=28.2, two articles), BMJ (IF 27.6), Lancet Oncol, J Thorac Oncol (IF=12.5), Chest and other journals. He has made conference speeches (6 times) or poster presentations at important international academic conferences such as ASCO, ESMO, WCLC and won the ASCO Merit Award (the first in domestic to win a grand slam at four major lung cancer academic conference). Served as a reviewer for many SCI journals such as BMJ and Lung Cancer. Host the National Nature/Youth, Guangzhou Key Special Project, etc. As a PI or sub-PI, he presided over 5 national multi-center clinical studies. One of the winners of the second prize of National Science and Technology Progress Award and the first prize of Chinese Medical Science and Technology Award. He was awarded the ‘National Famous Doctor’ by People’s Daily Online, CSCO’s 35 Most Promising Young Oncologists, and CSCO Lung Cancer Guidelines Expert Advisor.

Professor Li Shuben, Massachusetts General Hospital, Harvard University

  • Harvard Medical School Postdoc
  • Research Fellow, Massachusetts General Hospital, Harvard University, USA
  • Vice Chairman of the Thoracic Surgery Branch of the Chinese Anti-Cancer Association Rehabilitation Association
  • Member of the Thoracic Surgery Branch of Guangdong Medical Association
  • Deputy Leader of the Youth Committee of Thoracic Surgery, Guangdong Medical Association
  • Won "Outstanding Young Medical Talent in Guangdong Province" and "Key High-level Medical Talent in Guangzhou"
  • Focus on diagnosis and treatment of tracheal and lung surgery
  • Presided over many topics such as national key special projects related to tracheal surgery
  • Won the first prize of China Medical Science and Technology Award, the first prize of China Medical Science Award, and the first prize of Guangdong Science and Technology Progress Award
  • Obtained a national utility patent related to tracheal surgery technology

Professor Zhou Qinghua

  • Professor of Surgery and Oncology, Doctoral Supervisor
  • Director of Lung Cancer Center, West China Hospital of Sichuan University, Director of Lung Cancer Research Institute
  • Former Vice President of Tianjin Medical University, Former President of Tianjin Medical University General Hospital
  • Director of Tianjin Lung Cancer Research Institute, Director of Tianjin Key Laboratory of Lung Cancer Metastasis
  • Honorary Chairman of the Lung Cancer Committee of the Chinese Anti-Cancer Association
  • Chairman of the Chinese Anti-Cancer Association Tumor Metastasis Committee
  • Leader of the Expert Team for Early Diagnosis and Treatment of Lung Cancer, Ministry of Health of China
  • Expert of International Lung Cancer Screening and Early Diagnosis Expert Group
  • Member of the Academic Committee of the International Society of Tumor Metastasis
  • Expert of NIH Lung Cancer Early Diagnosis Marker Expert Group
  • US NIH-EDRN Lung Cancer Expert Group Expert
  • Editor-in-Chief of "Thoracic Cancer "
  • Editor-in-Chief of "Chinese Journal of Lung Cancer"

Professor Zhou Chengzhi, Doctor, chief physician, master supervisor

  • Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, National Medical Center for Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, State Key Laboratory of Respiratory Diseases
  • Director of Respiratory Zone 5 (Tumor Zone 1), Assistant Director of Cancer Center
  • Member of the Lung Cancer Group of the Respiratory Branch of the Chinese Medical Association
  • Member of the Lung Cancer Working Group of the Respiratory Branch of the Chinese Medical Doctor Association
  • Secretary-General of China Respiratory Tumor Cooperation Group and Deputy Chairman of Youth Committee
  • Member of Youth Committee and Patient Education Committee of Chinese Society of Clinical Oncology (CSCO)
  • Chairman of the Oncology Critical Care Committee of Guangdong Thoracic Oncology Society
  • Chairman of the Lung Cancer Branch of Guangdong Academy of Precision Medicine Application
  • Deputy Leader of Lung Cancer Group, Respiratory Medicine Branch of Guangdong Medical Association
  • Deputy Chairman of the Pulmonary Oncology Branch of the Guangdong Medical Association
  • Deputy Chairman of the Oncology Branch of the Guangdong Medical Association

Professor Cui Jiuwei, The First Hospital of Jilin University

  • Director of Oncology Department, Cancer Center, Jilin University First Hospital
  • Head of the Key Laboratory of Biotherapy of Jilin Province
  • Deputy Director, Institute of Cancer Research, Jilin University
  • Vice Chairman of the First Youth Council of China Anti-Cancer Association
  • Vice Chairman of Biotherapy Committee of China Research Hospital
  • Vice Chairman of the Molecular Diagnosis Committee of China Research Hospital
  • Vice Chairman of the Professional Committee of Cell Therapy Quality Control and Research, China Medical Quality Management Association
  • Secretary General of the Cancer Nutrition Professional Committee of the Chinese Anti-Cancer Association
  • Director of Chinese Society of Clinical Oncology (CSCO)
  • Member of China Lung Cancer Clinical Trial Cooperative Group (CTONG)
  • Chairman of Jilin Provincial Geriatric Oncology Society
  • Chairman of Oncology Branch of Jilin Research Hospital Association

Dr. Kang Li, Senior Vice President of BeiGene

  • Nearly 30 years of scientific research experience in biomedicine, tumor biology, antibody drug development and tumor immunotherapy
  • Former Sino-American Crown Division-Executive Director of Pfizer Asia Cancer Drug Research Center
  • Former Senior Chief Scientist, La Jolla Pfizer Cancer Drug Research and Development Center, USA
  • Former senior scientist and project leader of Down Biotech/Genentech
  • Former Associate Professor of Texas State University Dallas Medical Center
  • PhD in Biochemistry and Molecular Biology, Emory University, USA
  • Master of Business Administration, University of Dallas
  • Master of Cytogenetics, Wuhan University

Professor Hu Jian, First Affiliated Hospital of Zhejiang University School of Medicine

  • Professor, Chief Physician, Doctoral Supervisor, Director of General Thoracic Surgery, Director of Zhejiang Lung Tumor Diagnosis and Treatment Technology Research Center
  • Qiushi Distinguished Expert of Zhejiang University, Chief Scientist of National Key Research and Development Plan of “13th Five-Year Plan"
  • Chairman of the Thoracic Surgery Branch of Zhejiang Medical Association, Chairman of the Special Committee of Lung Cancer Prevention and Control of Zhejiang Preventive Medicine Association,
  • Deputy Chairman of the Esophageal Cancer Professional Committee of Zhejiang Anticancer Association
  • Member of the Standing Committee of the Thoracic Surgeons Branch of the Chinese Medical Doctor Association
  • Member of the Standing Committee of the Chinese Medical Doctor Association Multidisciplinary Cancer Diagnosis and Treatment Committee
  • Deputy Leader of the Lung Cancer Group, Chinese Society of Thoracic and Cardiovascular Surgery
  • Vice Chairman of the Thoracic Surgery Professional Committee of Chinese Research Hospital Association
  • Vice Chairman of the Lung Cancer Medical Education Committee of China Medical Education Association
  • Vice Chairman of the Thoracic Surgery Professional Committee of China Medical Education Association
  • Member of the Standing Committee of the Medical Robotic Physician Branch of the Chinese Medical Doctor Association
  • Member of the Standing Committee of the Thoracic Surgery Branch of China Association for the Promotion of International Healthcare Exchange
  • Deputy Chairman of the Thoracic Surgery Expert Committee of the Medical Robot Branch of the Chinese Medical Doctor Association
  • Deputy Chairman of the Minimally Invasive Expert Committee of the Thoracic Surgeons Branch of the Chinese Medical Doctor Association
  • Chairman of the Hand Surgery Expert Group of the Thoracic Surgeons Branch of the Chinese Medical Doctor Association
  • Evaluation expert of the Medical Device Technology Evaluation Center of the State Drug Administration
  • National health emergency response guidance expert
  • President- Designate of the Thoracic Surgeons Branch of Zhejiang Medical Doctor Association
  • Chairman of CLCU Zhejiang Province Alliance of Chinese Thoracic Surgery Lung Cancer Alliance

Professor Ma Haitao, Chief Physician, Doctoral Supervisor

  • Chief Expert of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Discipline Leader
  • Standing Committee Member of Thoracic Surgery Branch of Chinese Medical Doctor Association
  • Member of the Standing Committee of Thoracoscopy Professional Committee of Chinese Medical Doctor Association Endoscope Branch
  • Member of the Standing Committee of the Thoracic Surgery Branch of China Association for the Promotion of International Healthcare Exchanges
  • Member of the Lung Cancer Group of Thoracic and Cardiovascular Surgery, Chinese Medical Association
  • Member of the Standing Committee of CSCO Non-Small Cell Lung Cancer Professional Committee
  • Vice President of Thoracic Surgery Branch of Jiangsu Medical Association
  • Deputy Chairman of the Thoracic Surgery Branch of Jiangsu Medical Association, Leader of the Esophageal Cancer Group
  • Vice Chairman of the Lung Cancer Professional Committee of Jiangsu Anti-Cancer Association
  • Member of the Standing Committee of the Minimally Invasive Tumor Therapy Professional Committee of Jiangsu Anti-Cancer Association and Leader of the Endoscopy Group
  • Deputy Leader of Esophageal Cancer Group, Oncology Branch of Jiangsu Medical Association
  • Deputy Chairman of the Esophageal Cancer Professional Committee of Jiangsu Cancer Prevention and Treatment Union
  • Editorial board member of Chinese Journal of Lung Cancer, Chinese Journal of Thoracic Surgery (electronic version), Journal of Oncology, etc.

Professor Cheng Chao, MD, Chief Physician, Doctoral Student, Postdoctoral Supervisor

  • Guangdong Outstanding Young Medical Talent
  • Deputy Chairman of the Thoracic Surgery Branch of Guangdong Medical Association
  • Deputy Chairman of the Youth Committee of Thoracic Surgery, Guangdong Medical Association
  • Deputy Chairman of the Oncology Surgery Branch of the Guangdong Medical Association
  • Deputy Chairman of Guangdong Thoracic Cancer Research Association
  • Deputy Chairman of Guangdong Provincial Lung Cancer Professional Committee
  • Deputy Chairman of the Thoracic Surgery Branch of Guangdong Medical Industry Association
  • 2012-2013 Exchange Visiting Scholar US Johns Hopkins-Sun Yat-sen University

Professor Zhang Haibo, Chief physician, professor, doctoral supervisor

  • Director of Department of Oncology, Guangdong Provincial Hospital of Traditional Chinese Medicine; PI of Tumor Syndrome Differentiation, Treatment and Precision Treatment Team
  • Visiting Professor of MD·Anderson Cancer Center (MDACC) Memorial Sloan Kettering Cancer Center (MSKCC); Visiting Professor of Macau University of Science and Technology
  • Outstanding young medical talents in Guangdong Province; training target of "Thousand Hundred and Ten" engineering talents in Guangdong Province.
  • Vice-chairman of the WCFCC Tumor Precision Therapy Professional Committee; member of the CSCO Youth Committee; deputy chairman of the Cancer Molecular Targeted Therapy Committee of Guangdong Medical Doctor Association; deputy chairman of the Tumor Immunotherapy Professional Committee of Guangdong Thoracic Disease Society; Vice Chairman of Traditional Medicine Professional Committee of Cancer Society
  • Presided over 1 major research and development project of the Ministry of Science and Technology, 2 research projects of the National Natural Science Foundation of China, 1 major special project of Guangzhou Health and Medical Collaborative Innovation; 2 international cooperation projects, and more than 10 provincial and ministerial projects. Published more than 60 papers (12 SCI papers as the first and corresponding author)
  • Complimentary & Alternative Medicine; Chinese edition of Annals of oncology, Journal of Difficult and Intractable Diseases; Reviewer of Cancer Immunology, Immunotherapy; Lung Cancer; Integrative Cancer Therapies

Professor Zhu Yuming

  • Executive Director of Thoracic Surgery, Shanghai Pulmonary Hospital
  • Member of the Thoracic Surgery Group of the Chinese Society of Thoracic and Cardiovascular Surgery, Member of the Thoracic Surgery Branch of the Chinese Society of Integrated Chinese Medicine Committee Member of the Thoracic Surgery Branch of the Shanghai Medical Association, Deputy Chairman of the Thoracic Surgery Branch of the Shanghai Association of Integrative Medicine Deputy Chairman of the Minimally Invasive Surgery Group of the Thoracic Surgery Branch of the Shanghai Medical Doctor Association Chairman of the Lung Cancer Surgery Group of the Thoracic Oncology Committee of the Shanghai Anti-Cancer Association

Professor Jiang Tao

  • Chief physician, master and doctoral supervisor
  • Director of Thoracic Surgery, Tangdu Hospital, Air Force Military Medical University
  • Chairman of Xi'an Thoracic Surgery Branch of Chinese Medical Association
  • Member of the Thoracic Surgeons Branch of the Chinese Medical Doctor Association
  • Director of the First Council of Xi'an Anti-Cancer Society
  • Vice Chairman of the Rare Tumor Professional Committee of Shaanxi Anti-Cancer Association
  • Vice Chairman of the Esophageal Cancer Professional Committee of Shaanxi Anti-Cancer Association
  • Vice Chairman of the Lung Cancer Professional Committee of Shaanxi Anti-Cancer Association
  • Vice Chairman of the Tumor Metastasis Professional Committee of Shaanxi Anticancer Association
  • Presided over 8 scientific research projects at various levels including the National Natural Science Foundation of China/Shaanxi Provincial Key Research and Development Project, published more than 20 SCI papers as the first/corresponding author, edited 5 Chinese and English monographs, and served as the "Journal of Trauma Surgery" Standing editor and so on.

Professor Tan Fengwei, Cancer Hospital Chinese Academy of Medical Sciences

  • Deputy Director of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences
  • Doctor of Clinical Medicine, Doctor of Molecular Biology, Deputy Chief Physician
  • Member of the Chinese Medical Association Thoracic and Cardiovascular Surgery Branch
  • Member of the Thoracic Surgery Branch of the Chinese Medical Doctor Association, deputy chairman of the Youth Committee
  • CSCO Deputy Secretary-General, Member of Lung Cancer/Esophageal Cancer Expert Committee
  • Standing Director of Youth Council of China Anti-Cancer Association
  • Member of the Thoracic Surgery Branch of the Beijing Medical Association, Deputy Chairman of the Youth Committee
  • Deputy Secretary General of Youth Council of Beijing Anti-Cancer Association
  • Member of Esophageal Cancer Committee of Chinese Anti-Cancer Association, Youth Committee of Lung Cancer Committee
  • Presided over 12 projects at all levels, including the National Key Research and Development Program, the National Natural Science Foundation, the Central Health Science Research Project, and the first special project of the Beijing Science and Technology Plan. The achievements in the early diagnosis of lung cancer have obtained 3 national patents and 1 international patent.
  • Won the honorary titles of the 6th Beijing Outstanding Physician, the National Famous Doctor in 2019. Young New Talent, and the 2018 Honorary Doctor. Youth Innovation Award.

Professor Zhang Peng, Shanghai Pulmonary Hospital Affiliated to Tongji University

  • Director of the Thoracic Surgery, Deputy Chief Physician, Professor, Doctoral Supervisor
  • Winner of National Outstanding Youth Fund
  • Deputy Chairman of the Youth Committee of the Chinese Medical Association Thoracic and Cardiovascular Surgery Branch
  • Professor Gu Chundong, The First Affiliated Hospital of Dalian Medical University
  • Director of Thoracic Surgery Department and Doctoral Supervisor of the First Affiliated Hospital of Dalian Medical University
  • Subject leader of Dalian lung cancer diagnosis and treatment base
  • Chief Scientist of Dalian Lung Cancer Tissue Gene Bank Engineering Laboratory
  • Deputy Chairman of the Thoracic Surgery Committee of the Cross-Strait Medical and Health Exchange Association of the Health and Family Planning Commission
  • Member of the Lung Cancer Group of the Chinese Medical Association Thoracic and Cardiovascular Surgery Branch
  • Member of the Thoracoscopy Surgery Group of the Chinese Medical Association Thoracic and Cardiovascular Surgery Branch
  • Standing Committee Member of the Professional Committee of Tumor Ablation Therapy of China Anti-Cancer Association
  • Member of the Standing Committee of the Thoracic Surgery Branch of China Association for the Promotion of International Healthcare Exchange
  • Member of the Thoracic Surgery Branch of the Chinese Medical Doctor Association
  • Member of the Professional Committee of Tobacco Control and Lung Cancer Prevention and Treatment of China Tobacco Control Association
  • Vice Chairman of Thoracic Surgery of Liaoning Province, Chinese Medical Doctor Association
  • Vice Chairman of Liaoning Thoracic Surgery Branch of Chinese Medical Association
  • Chairman-designate of the Liaoning Provincial Esophageal Cancer Professional Committee of the Chinese Anti-Cancer Association
  • Vice Chairman of Liaoning Lung Cancer Professional Committee of China Anti-Cancer Association
  • Deputy Leader of the Minimally Invasive Diagnosis and Treatment Group of Lung Cancer, Lung Cancer Prevention and Control Branch of China Medical Promotion Association
  • Vice Chairman of the Cancer Nutrition Professional Committee of China Anti-aging Promotion Association
  • Member of International Association for Lung Cancer Research
  • Member of Japanese Association for Chest Surgery
  • Professor Wang Dong, Taikang Xianlin Drum Tower Hospital, Nanjing University School of Medicine
  • Director of Thoracic Surgery, Chief Physician, Professor
  • Member of the Thoracic Surgeons Branch of the Chinese Medical Doctor Association and deputy leader of the Chest Wall and Mediastinology Group;
  • Deputy Chairman of the Thoracic Surgery Branch of Jiangsu Medical Association and Leader of the Lung Cancer Group;
  • Vice President of Thoracic Surgery Branch of Jiangsu Medical Association;
  • Vice Chairman of the Chinese Anti-Cancer Association Tumor Marker Professional Committee;
  • Member of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association;
  • Executive director of Jiangsu Anti-Cancer Association;
  • Executive Vice Chairman of Jiangsu Lung Cancer Professional Committee;
  • Vice Chairman of Jiangsu Provincial Esophageal Cancer Professional Committee;

Professor Pan Xiaojie

  • Position / Title
  • Chief Physician, Associate Professor, Administrative Director of Thoracic Surgery, Fujian Provincial Hospital, Master's Tutor of Fujian Medical University
  • Main academic positions
  • Standing Committee Member of Thoracic Surgery Branch of China Medical Education Association
  • National Committee of Thoracic Surgery Branch of Chinese Medical Doctor Association
  • National Committee of Mediastinal Tumor Professional Committee of China Anti-Cancer Association
  • The First National Committee of the Thoracic Surgery Branch of the Research Hospital Association
  • National Committee of the Thoracic Surgery Branch of the Cross-Strait Medical Promotion Association
  • Vice President of the Thoracic Surgery Branch of Fujian Medical Doctor Association
  • Vice President of the Thoracic Oncology Branch of Fujian Strait Medical and Health Exchange Association
  • Deputy Chairman of the Thoracic Surgery Branch of Fujian Medical Association
  • Standing Committee Member of Esophageal Cancer Professional Committee of Fujian Anti-Cancer Association
  • Editorial Board Member of the Chinese Medical Reference Journal of Thoracic and Cardiovascular Surgery Channel
  • Presided over and participated in a number of scientific research projects at the provincial level and the Department of Health
  • Main technical features
  • Good at diagnosis and precise treatment of thoracic malignant tumors, especially good at minimally invasive surgical treatment of lung cancer, esophageal cancer, cardia cancer, and mediastinal tumors

Professor Lei Guangyan, Shaanxi Cancer Hospital

  • Chief physician, master supervisor
  • Director of Thoracic Surgery, Shaanxi Cancer Hospital
  • Executive Director of Shaanxi Anti-Cancer Association
  • Chairman of the Professional Committee of Minimally Invasive Tumor Therapy of Shaanxi Anticancer Association
  • Vice Chairman of Lung Cancer Professional Committee, Tumor Metastasis Professional Committee, Electrochemical Therapy Professional Committee
  • Vice Chairman of Minimally Invasive Surgery Branch, Lung Cancer Minimally Invasive Comprehensive Treatment Branch
  • Standing Committee Member of Esophageal Cancer Professional Committee
  • Member of the Standing Committee of the China Anti-Cancer Association Minimally Invasive Tumor Therapy Committee
  • Member of the Standing Committee of the Oncology Committee of the Chinese National Health Association
  • Member of the Esophageal Cancer Professional Committee of the Chinese Anti-Cancer Association
  • Member of the Thoracic Surgery Committee of the Chinese Medical Doctor Association
  • Reviewer of "Modern Cancer Medicine"

____________________________________________________________________________

Immunotherapy for Resectable Non-Small Cell Lung Cancer

ASCO Abstract # LBA5

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

ASCO Abstract # 9041

Peripheral blood T-cell receptor immune repertoire characterization of resectable stage IIIA non-small cell lung cancer patients receiving neo-adjuvant chemo-immunotherapy treatment from NADIM study

ASCO Abstract # 99

Neoadjuvant atezolizumab in resectable NSCLC patients: Updated clinical and immunophenotyping results from a multicenter trial (LCMC3 Trial)


If you need to request a copy of the abstract, please send email to "webinars@eChinaHealth.com”.

Disclaimers: ASCO and eChinaHealth do not endorse any health care product, therapy, diagnostic test or device.


Organizers:

                                              

                                      

                                      

Partners:

                                              

Exclusive Live Streaming Platform: